1. Cheng YM, Lin PL, Wu DW, et al. PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2. Oncotarget 2018;9, 26342-26352.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417, 949-954.
3. Liu X, Jakubowski M, Hunt JL. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am. J. Clin. Pathol. 2011;135, 245-252.
4. Mei ZB, Duan CY, Li, C.B., et al. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann. Oncol. 2016;27, 1836- 1848.
5. Shahi Thakuri P, Luker GD, Tavana H. Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors. Transl. Oncol. 2019;12, 404-416.
6. Douillard JY, Siena S, Cassidy J. Randomized, et al. phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28: 4697–4705.
7. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014;15: 569–579.
8. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25: 1658– 1664.
9. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan(FOLFIRI) compared with FOLFIRI alone as secondline treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28: 4706–4713.
10. Topf JM, Murray PT. Hypomagnesemia and hypermagnesemia. Rev Endocr Metab Disord. 2003;May;4(2): 195-206.
11. Rockville MD. Proton pump inhibitor drugs (PPIs): Drug Safety Communication-low magnesium levels can be associated with long-term use: US Food and Drug Administration, 2011.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417, 949-954.
13. Liu X, Jakubowski M, Hunt JL. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am. J. Clin. Pathol. 2011;135, 245-252.
14. Shahi Thakuri P, Luker GD, Tavana H. Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors. Transl. Oncol. 2019;12, 404-416.
15. Satake H, Sunakawa Y, Miyamoto Y, et al. A phase II trial of 1st-line modified- FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget 2018;9, 18811-18820.
16. DeStefanis RA, Kratz JD, Emmerich PB, et al. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. Curr. Colorectal Cancer Rep. 2019;15, 61-69.
17. Corcoran RB, André T, Atreya CE, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018;8, 428-443.
18. Hong DS, Morris VK, Osta EIB, et al. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016;6, 1352-1365.
19. Kidera Y, Tsubaki M, Yamazoe Y, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho- associated coiled-coil-containing protein kinase pathway. J. Exp. Clin. Cancer Res. 2010;29, 127.
20. Tsubaki M, Komai M, Itoh T, et al. Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation. J. Biomed. Sci. 2014;21, 10.
21. Kontos CK, Avgeris M, Vassilacopoulou D, et al. Molecular Effects of Treatment of Human Colorectal Cancer Cells with Natural and Classical Chemotherapeutic Drugs: Alterations in the Expression of Apoptosis-related BCL2 Family Members, Including BCL2L12. Curr. Pharm. Biotechnol. 2018;19, 1064-1075.
22. Wang Q, Shi YL, Zhou K, et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis. 2018;9, 739.
23. Tsubaki M, Takeda T, Asano RT, et al. Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins. Toxicol. In Vitro 2018;46, 284-293.
24. Tsubaki M, Takeda T., Noguchi M, et al. Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells. Cancers 2019;11, 1866.
25. Yang S, Zhu Z, Zhang X, et al. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells. Oncotarget 2017;8, 6102-6113.
26. Lin J, Feng J, Yang H, et al. Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway. Oncol. Rep. 2017;38, 2293-2300.
27. Chung YH, Kim D. Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial-Mesenchymal Transition Through Phosphorylation of GSK3β. Anticancer Res. 2016;36, 3383-3394.
28. Wu H, Liang Y, Shen L, et al. MicroRNA-204 modulates colorectal cancer cell sensitivity in response to 5-fluorouracil-based treatment by targeting high mobility group protein A2. Biol. Open 2016;5, 563-570.
29. Leelawat K, Narong S, Udomchaiprasertkul W, et al. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int. 2009;9, 3.
30. Gu J, Li Z, Zhou J, et al. Response prediction to oxaliplatin plus 5-fluorouracil chemotherapy in patients with colorectal cancer using a four-protein immunohistochemical model. Oncol. Lett. 2019;18, 2091-2101.
31. Bendell JC, Nemunaitis J, Vukelja SJ, et al. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2011;29, 4394-4400.
32. Groenestege WM, Thébault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007; 117(8): 2260-2267.
33. Fakih M. Management of anti-EGFR-targeting monoclonal antibody-induced hypomagnesemia. Oncology (Williston Park) 2008;Jan 22(1): 74-76.
34. Eri N, Kazuyoshi K, Hiroshi I, et al. Retrospective Investigation on Cetuximab- induced Hypomagnesemia ; Incidence, Time of Onset, and Management. Jpn. J. Pharm. Health Care Sci. 2011;37(7): 403 -409
35. Zhang J, Zhang C, Li Q, et al. C-Reactive Protein/Albumin Ratio Is an Independent Prognostic Predictor of Survival in Advanced Cancer Patients Receiving Palliative Care. J Palliat Med. 2019;22(12): 1536-1545.
36. Park CH, Kim EH, Roh YH, et al. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS One. 2014;9(11): e112558.
37. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8(5): 387-394.
38. Tso EL, Barish RA. Magnesium: clinical considerations. J Emerg Med. 1992;Nov- Dec;10(6): 735-45.
39. Wang Q, Qi Y, Zhang D, et al. (2015) Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: A pooled analysis of 25 randomized clinical trials. Tumour Biol. 2015;May;36(5): 3471-82.
40. Wakai E, Ikemura K, Sugimoto H, et al. Risk factors for the development of hypermagnesemia in patients prescribed magnesium oxide: a retrospective cohort study. J Pharm Health Care Sci. 2019;Feb 13; 5: 4.
41. Massy ZA, Nistor I, Apetrii M, et al. Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnes Res. 2016;29(4): 126-140.
42. Oka T, Hamano T, Sakaguchi Y, et al. Proteinuria-associated renal magnesium wasting leads to hypomagnesemia: a common electrolyte abnormality in chronic kidney disease. Nephrol Dial Transplant. 2019;34(7): 1154-1162.
43. Hughes J, Y Chiu D, Kalra PA, et al. Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease. PLoS One. 2018;13(5): e0197400.
44. Xie Y, Bowe B, Li T, et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6): 1482-1494.
45. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634): 2-3.
46. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;Apr;22(2): 205-10.
47. Kieboom BC, Kiefte-de Jong JC, Eijgelsheim M et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis. 2015;Nov 66(5): 775-82.